Artax Biopharma Announces the Formation of Scientific Advisory Board to Advance Autoimmune Disease Therapy AX-158

Artax Biopharma, Inc., a biotechnology company focused on transforming autoimmune disease treatment, today announces the formation of their Scientific Advisory Board (SAB). The SAB is comprised of experts in Immunology, Autoimmune Disease, and T Cell Signaling, and was formed to guide the company as it proceeds into future clinical trials with a first-in-class, oral small molecule autoimmune disease immunomodulator AX-158.

Artax Biopharma is poised to enter clinical trials with the small molecule AX- 158, a novel approach to treat multiple autoimmune diseases without causing the immunosuppression commonly associated with current autoimmune disease therapies.

Balbino Alarcón, PhD, Chairman of Artax's Scientific Advisory Board, commented, "I am privileged to lead Artax's Scientific Advisory Board, which mobilizes global leaders in Immunology, Autoimmune Disease, and T Cell Signaling. Collectively we are enthusiastic to collaborate on, and contribute to, important development initiatives related to Artax's innovative approach to autoimmune disease treatment."

"Artax Biopharma's Nck inhibitor AX-158 has shown impressive experimental biologic and mechanistic impact on T cell modulation - managing autoimmune disease without inducing the profound immunosuppression or interference with memory response associated with conventional or biological therapies," stated Dr. Lawrence Steinman, Stanford University Zimmerman Professor of Neurology and Neurosciences, Pediatrics, and Genetics and Scientific Advisory Board member.

"Convening a Scientific Advisory Board is a critical step as we accelerate our clinical development program," stated Artax Biopharma Chief Executive Officer Joseph Lobacki. "The clinical expertise and knowledge of these experts is unparalleled and will be instrumental in informing our development strategy across several autoimmune diseases."

The SAB will be comprised of five experts, and is being led by Professor Balbino Alarcón, PhD, co-founder of Artax Biopharma: